The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Multiple Wearable Sensors in Parkinson and Huntington Disease Individuals: A Pilot Study in Clinic and at Home
Open accessAbstract
Background: Clinician rating scales and patient-reported outcomes are the principal means of assessing motor symptoms in Parkinson disease and Huntington disease. However, these assessments are subjective and generally limited to episodic in-person visits. Wearable sensors can objectively and continuously measure motor features and could be valuable in clinical research and care. Methods: We recruited participants with Parkinson disease, Huntington disease, and prodromal Huntington disease (individuals who carry the genetic marker but do not yet exhibit symptoms of the disease), and controls to wear 5 accelerometer-based sensors on their chest and limbs for standardized in-clinic assessments and for 2 days at home. The study’s aims were to assess the feasibility of use of wearable sensors, to determine the activity (lying, sitting, standing, walking) of participants, and to survey participants on their experience. Results: Fifty-six individuals (16 with Parkinson disease, 15 with Huntington disease, 5 with prodromal Huntington disease, and 20 controls) were enrolled in the study. Data were successfully obtained from 99.3% (278/280) of sensors dispatched. On average, individuals with Huntington disease spent over 50% of the total time lying down, substantially more than individuals with prodromal Huntington disease (33%, p = 0.003), Parkinson disease (38%, p = 0.01), and controls (34%; p < 0.001). Most (86%) participants were “willing” or “very willing” to wear the sensors again. Conclusions: Among individuals with movement disorders, the use of wearable sensors in clinic and at home was feasible and well-received. These sensors can identify statistically significant differences in activity profiles between individuals with movement disorders and those without. In addition, continuous, objective monitoring can reveal disease characteristics not observed in clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418
Technology in Parkinson’s disease: challenges and opportunities
Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., Eskofier, B. M., Merola, A., Horak, F., Lang, A. E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26642 · Cited by 654
Self-citationMannini, A., Trojaniello, D., Cereatti, A., & Sabatini, A. (2016) · Sensors · doi:10.3390/s16010134 · Cited by 242
Novel Methods and Technologies for 21st-Century Clinical Trials: A Review
Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4524 · Cited by 118
Self-citation
Research works printed but not linked: 14
- 10.1016/j.drudis.2016.01.010 · DOI
- 10.1002/mds.25628 · DOI · Paper page
- 10.1016/S1474-4422(10)70245-3 · DOI · Paper page
- 10.1002/mds.22340 · DOI · Paper page
- 10.1002/mds.870110204 · DOI · Paper page
- 10.1016/j.gaitpost.2016.11.033 · DOI
- 10.1002/1531-8249(200001)47:1<64::AID-ANA11>3.3.CO;2-J · DOI
- 10.1016/j.jns.2016.03.021 · DOI
- 10.2217/nmt.15.45 · DOI
- 10.1002/ana.24495 · DOI
- 10.1016/j.jneumeth.2016.01.009 · DOI
- 10.2522/ptj.20140374 · DOI
- 10.1016/j.parkreldis.2013.05.014 · DOI
- 10.1007/s00415-011-6097-7 · DOI · Paper page
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications
Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2525967 · Cited by 810
Luen Tang, B. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2318 · Cited by 740
Technology in Parkinson’s disease: challenges and opportunities
Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., Eskofier, B. M., Merola, A., Horak, F., Lang, A. E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26642 · Cited by 654
Self-citationThe mPower study, Parkinson disease mobile data collected using ResearchKit
Bot, B. M., Suver, C., Neto, E. C., Kellen, M., Klein, A., Bare, C., Doerr, M., Pratap, A., Wilbanks, J., Dorsey, E. R., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.11 · Cited by 630
Self-citationApplications of machine learning to diagnosis and treatment of neurodegenerative diseases
Myszczynska, M. A., Ojamies, P. N., Lacoste, A. M. B., Neil, D., Saffari, A., Mead, R., Hautbergue, G. M., Holbrook, J. D., & Ferraiuolo, L. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0377-8 · Cited by 595
Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554
Schenkman, M., Moore, C. G., Kohrt, W. M., Hall, D. A., Delitto, A., Comella, C. L., Josbeno, D. A., Christiansen, C. L., Berman, B. D., Kluger, B. M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3517 · Cited by 515
Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing
Didiot, M.-C., Hall, L. M., Coles, A. H., Haraszti, R. A., Godinho, B. M., Chase, K., Sapp, E., Ly, S., Alterman, J. F., Hassler, M. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.126 · Cited by 483
Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428
Astrocytes in Neurodegenerative Disease: Table 1.
Phatnani, H., & Maniatis, T. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020628 · Cited by 420
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Kwok, J. Y. Y., Kwan, J. C. Y., Auyeung, M., Mok, V. C. T., Lau, C. K. Y., Choi, K. C., & Chan, H. Y. L. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0534 · Cited by 379
Cognitive Impairment in Huntington Disease: Diagnosis and Treatment
Paulsen, J. S. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0215-x · Cited by 364
Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging
Plaza-Zabala, A., Sierra-Torre, V., & Sierra, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030598 · Cited by 323
Potential function for the Huntingtin protein as a scaffold for selective autophagy
Ochaba, J., Lukacsovich, T., Csikos, G., Zheng, S., Margulis, J., Salazar, L., Mao, K., Lau, A. L., Yeung, S. Y., Humbert, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420103111 · Cited by 308
Yang, Y., Yuan, Y., Zhang, G., Wang, H., Chen, Y.-C., Liu, Y., Tarolli, C. G., Crepeau, D., Bukartyk, J., Junna, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01932-x · Cited by 296
Self-citationLow-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial
Phillips, M. C. L., Murtagh, D. K. J., Gilbertson, L. J., Asztely, F. J. S., & Lynch, C. D. P. (2018) · Movement Disorders · doi:10.1002/mds.27390 · Cited by 292
Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases
Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A., Polgreen, P. M., Narayanan, N. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129987 · Cited by 286
Lipsmeier, F., Taylor, K. I., Kilchenmann, T., Wolf, D., Scotland, A., Schjodt‐Eriksen, J., Cheng, W., Fernandez‐Garcia, I., Siebourg‐Polster, J., Jin, L., et al. (2018) · Movement Disorders · doi:10.1002/mds.27376 · Cited by 266
Teleneurology and mobile technologies: the future of neurological care
Dorsey, E. R., Glidden, A. M., Holloway, M. R., Birbeck, G. L., & Schwamm, L. H. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.31 · Cited by 258
Self-citationGodinho, C., Domingos, J., Cunha, G., Santos, A. T., Fernandes, R. M., Abreu, D., Gonçalves, N., Matthews, H., Isaacs, T., Duffen, J., et al. (2016) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-016-0136-7 · Cited by 226
Oxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly
Kumar, A., & Ratan, R. R. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160205 · Cited by 236
Fan, Z., Pan, Y.-T., Zhang, Z.-Y., Yang, H., Yu, S.-Y., Zheng, Y., Ma, J.-H., & Wang, X.-M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1670-6 · Cited by 228
The severity of psychiatric disorders
Zimmerman, M., Morgan, T. A., & Stanton, K. (2018) · World Psychiatry · doi:10.1002/wps.20569 · Cited by 227
Gene Therapy for Neurodegenerative Diseases
Sudhakar, V., & Richardson, R. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00694-0 · Cited by 212
Lonini, L., Dai, A., Shawen, N., Simuni, T., Poon, C., Shimanovich, L., Daeschler, M., Ghaffari, R., Rogers, J. A., & Jayaraman, A. (2018) · npj Digital Medicine · doi:10.1038/s41746-018-0071-z · Cited by 209
Fragile X-Associated Neuropsychiatric Disorders (FXAND)
Hagerman, R. J., Protic, D., Rajaratnam, A., Salcedo-Arellano, M. J., Aydin, E. Y., & Schneider, A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00564 · Cited by 204
Wasser, C. I., Mercieca, E.-C., Kong, G., Hannan, A. J., McKeown, S. J., Glikmann-Johnston, Y., & Stout, J. C. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa110 · Cited by 198
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study
Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020) · Movement Disorders · doi:10.1002/mds.28170 · Cited by 185
Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease
Silva de Lima, A. L., Hahn, T., Evers, L. J. W., de Vries, N. M., Cohen, E., Afek, M., Bataille, L., Daeschler, M., Claes, K., Boroojerdi, B., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189161 · Cited by 162
Computer-Aided diagnosis of Parkinson’s Disease Using Enhanced Probabilistic Neural Network
Hirschauer, T. J., Adeli, H., & Buford, J. A. (2015) · Journal of Medical Systems · doi:10.1007/s10916-015-0353-9 · Cited by 177
Fan, Y., Howden, A. J. M., Sarhan, A. R., Lis, P., Ito, G., Martinez, T. N., Brockmann, K., Gasser, T., Alessi, D. R., & Sammler, E. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170803 · Cited by 173
Evers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168
Wearable sensor-based objective assessment of motor symptoms in Parkinson’s disease
Ossig, C., Antonini, A., Buhmann, C., Classen, J., Csoti, I., Falkenburger, B., Schwarz, M., Winkler, J., & Storch, A. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-015-1439-8 · Cited by 164
The first frontier: digital biomarkers for neurodegenerative disorders
Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers · doi:10.1159/000477383 · Cited by 162
Self-citationThe P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Theranostic applications of nanoparticles in neurodegenerative disorders
Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., Gulyás, B., & Padmanabhan, P. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149022 · Cited by 161
Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain
Pearce, M. M. P., Spartz, E. J., Hong, W., Luo, L., & Kopito, R. R. (2015) · Nature Communications · doi:10.1038/ncomms7768 · Cited by 159
Microglial activation in the pathogenesis of Huntington's disease
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., & Guo, J.-F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00193 · Cited by 151
Impaired GAPDH‐induced mitophagy contributes to the pathology of Huntington's disease
Hwang, S., Disatnik, M., & Mochly‐Rosen, D. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505256 · Cited by 153
Mahadevan, N., Demanuele, C., Zhang, H., Volfson, D., Ho, B., Erb, M. K., & Patel, S. (2020) · npj Digital Medicine · doi:10.1038/s41746-019-0217-7 · Cited by 138
Probiotics may have beneficial effects in parkinson’s disease: In vitro evidence
Magistrelli, L., Amoruso, A., Mogna, L., Graziano, T., Cantello, R., Pane, M., & Comi, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00969 · Cited by 144
Marcroft, C., Khan, A., Embleton, N. D., Trenell, M., & Plötz, T. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2014.00284 · Cited by 146
REGISTRY Investigators of the European Huntington's Disease Network, Bečanović, K., Nørremølle, A., Neal, S. J., Kay, C., Collins, J. A., Arenillas, D., Lilja, T., Gaudenzi, G., Manoharan, S., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4014 · Cited by 135
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases
Chen, D., Zhang, T., & Lee, T. H. (2020) · Biomolecules · doi:10.3390/biom10081158 · Cited by 140
Reinertsen, E., & Clifford, G. D. (2018) · Physiological Measurement · doi:10.1088/1361-6579/aabf64 · Cited by 136
Sigcha, L., Costa, N., Pavón, I., Costa, S., Arezes, P., López, J. M., & De Arcas, G. (2020) · Sensors · doi:10.3390/s20071895 · Cited by 126
Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease
Schröder, J. B., Pawlowski, M., Meyer zu Hörste, G., Gross, C. C., Wiendl, H., Meuth, S. G., Ruck, T., & Warnecke, T. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01081 · Cited by 134
Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
Postuma, R. B., Anang, J., Pelletier, A., Joseph, L., Moscovich, M., Grimes, D., Furtado, S., Munhoz, R. P., Appel-Cresswell, S., Moro, A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004568 · Cited by 135
Genetic Changes Shaping the Human Brain
Bae, B.-I., Jayaraman, D., & Walsh, C. A. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.01.035 · Cited by 135
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Toosizadeh, N., Mohler, J., Lei, H., Parvaneh, S., Sherman, S., & Najafi, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124763 · Cited by 117
Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia
Saba, J., Couselo, F. L., Bruno, J., Carniglia, L., Durand, D., Lasaga, M., & Caruso, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666211201094608 · Cited by 117
Dentamaro, V., Impedovo, D., Musti, L., Pirlo, G., & Taurisano, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-70165-4 · Cited by 116
Chaperone‐mediated autophagy: Molecular mechanisms, biological functions, and diseases
Yao, R., & Shen, J. (2023) · MedComm · doi:10.1002/mco2.347 · Cited by 111
Ferreira, J. J., Godinho, C., Santos, A. T., Domingos, J., Abreu, D., Lobo, R., Gonçalves, N., Barra, M., Larsen, F., Fagerbakke, Ø., et al. (2015) · BMC Neurology · doi:10.1186/s12883-015-0343-z · Cited by 96
The microbiota–microglia axis in central nervous system disorders
Mossad, O., & Erny, D. (2020) · Brain Pathology · doi:10.1111/bpa.12908 · Cited by 98
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study
Adams, J. L., Kangarloo, T., Tracey, B., O’Donnell, P., Volfson, D., Latzman, R. D., Zach, N., Alexander, R., Bergethon, P., Cosman, J., et al. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00497-x · Cited by 98
Self-citationMobile and pervasive computing technologies and the future of Alzheimer’s clinical trials
Doraiswamy, P. M., Narayan, V. A., & Manji, H. K. (2018) · npj Digital Medicine · doi:10.1038/s41746-017-0008-y · Cited by 97
Therapeutic reversal of Huntington’s disease by in vivo self-assembled siRNAs
Zhang, L., Wu, T., Shan, Y., Li, G., Ni, X., Chen, X., Hu, X., Lin, L., Li, Y., Guan, Y., et al. (2021) · Brain · doi:10.1093/brain/awab354 · Cited by 97
Nuclear pore complexes — a doorway to neural injury in neurodegeneration
Coyne, A. N., & Rothstein, J. D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00653-6 · Cited by 96
Ochaba, J., Monteys, A. M., O’Rourke, J. G., Reidling, J. C., Steffan, J. S., Davidson, B. L., & Thompson, L. M. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.016 · Cited by 94
Iakovakis, D., Hadjidimitriou, S., Charisis, V., Bostantzopoulou, S., Katsarou, Z., & Hadjileontiadis, L. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25999-0 · Cited by 92
MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders
Han, D., Dong, X., Zheng, D., & Nao, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01555 · Cited by 90
Mutant Huntingtin Is Secreted via a Late Endosomal/Lysosomal Unconventional Secretory Pathway
Trajkovic, K., Jeong, H., & Krainc, D. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0118-17.2017 · Cited by 85
Body-worn sensors in Parkinson’s disease: evaluating their acceptability to patients
Fisher, J. M., Hammerla, N. Y., Rochester, L., Andras, P., & Walker, R. W. (2016) · Telemedicine and e-Health · doi:10.1089/tmj.2015.0026 · Cited by 81
Mindfulness Training among Individuals with Parkinson’s Disease: Neurobehavioral Effects
Pickut, B., Vanneste, S., Hirsch, M. A., Van Hecke, W., Kerckhofs, E., Mariën, P., Parizel, P. M., Crosiers, D., & Cras, P. (2015) · Parkinson's Disease · doi:10.1155/2015/816404 · Cited by 80
In vivo characterization of white matter pathology in premanifest huntington's disease
Zhang, J., Gregory, S., Scahill, R. I., Durr, A., Thomas, D. L., Lehericy, S., Rees, G., Tabrizi, S. J., Zhang, H., & the TrackOn‐HD investigators (2018) · Annals of Neurology · doi:10.1002/ana.25309 · Cited by 80
Mindfulness for Motor and Nonmotor Dysfunctions in Parkinson’s Disease
Dissanayaka, N. N. W., Idu Jion, F., Pachana, N. A., O’Sullivan, J. D., Marsh, R., Byrne, G. J., & Harnett, P. (2016) · Parkinson's Disease · doi:10.1155/2016/7109052 · Cited by 79
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Tetzloff, K. A., Graff-Radford, J., Martin, P. R., Tosakulwong, N., Machulda, M. M., Duffy, J. R., Clark, H. M., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170740 · Cited by 78
Payne, T., Appleby, M., Buckley, E., van Gelder, L. M. A., Mullish, B. H., Sassani, M., Dunning, M. J., Hernandez, D., Scholz, S. W., McNeill, A., et al. (2023) · Movement Disorders · doi:10.1002/mds.29450 · Cited by 76
Machine Learning in Human Olfactory Research
Lötsch, J., Kringel, D., & Hummel, T. (2019) · Chemical Senses · doi:10.1093/chemse/bjy067 · Cited by 71
Neuroimaging in Parkinson’s disease dementia: connecting the dots
Weil, R. S., Hsu, J. K., Darby, R. R., Soussand, L., & Fox, M. D. (2019) · Brain Communications · doi:10.1093/braincomms/fcz006 · Cited by 71
Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., et al. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-223433 · Cited by 70
Boxer, A. L., Gold, M., Feldman, H., Boeve, B. F., Dickinson, S. L.-J., Fillit, H., Ho, C., Paul, R., Pearlman, R., Sutherland, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.4956 · Cited by 71
Self-citationDeveloping a Tool for Remote Digital Assessment of Parkinson's Disease
Kassavetis, P., Saifee, T. A., Roussos, G., Drougkas, L., Kojovic, M., Rothwell, J. C., Edwards, M. J., & Bhatia, K. P. (2016) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12239 · Cited by 69
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial
Moonen, A. J. H., Mulders, A. E. P., Defebvre, L., Duits, A., Flinois, B., Köhler, S., Kuijf, M. L., Leterme, A., Servant, D., de Vugt, M., et al. (2021) · Movement Disorders · doi:10.1002/mds.28533 · Cited by 71
A proteogenomic view of Parkinson’s disease causality and heterogeneity
Kaiser, S., Zhang, L., Mollenhauer, B., Jacob, J., Longerich, S., Del-Aguila, J., Marcus, J., Raghavan, N., Stone, D., Fagboyegun, O., et al. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00461-9 · Cited by 68
Rutten, S., Vriend, C., van der Werf, Y. D., Berendse, H. W., Weintraub, D., & van den Heuvel, O. A. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.01.015 · Cited by 66
GABA release from astrocytes in health and disease.
Kilb, W., & Kirischuk, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415859 · Cited by 66
Rusch, C., Beke, M., Tucciarone, L., Nieves, C., Ukhanova, M., Tagliamonte, M. S., Mai, V., Suh, J. H., Wang, Y., Chiu, S., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.794640 · Cited by 63
Mindfulness-based stress reduction in Parkinson’s disease: a systematic review
McLean, G., Lawrence, M., Simpson, R., & Mercer, S. W. (2017) · BMC Neurology · doi:10.1186/s12883-017-0876-4 · Cited by 59
Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160776 · Cited by 58
Lubomski, M., Xu, X., Holmes, A. J., Muller, S., Yang, J. Y. H., Davis, R. L., & Sue, C. M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.875261 · Cited by 59
Kwok, J. Y. Y., Kwan, J. C. Y., Auyeung, M., Mok, V. C. T., & Chan, H. Y. L. (2017) · Trials · doi:10.1186/s13063-017-2223-x · Cited by 56
Primary cilia and autophagic dysfunction in Huntington’s disease
Kaliszewski, M., Knott, A. B., & Bossy-Wetzel, E. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.80 · Cited by 55
Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome
Tetzloff, K. A., Duffy, J. R., Clark, H. M., Utianski, R. L., Strand, E. A., Machulda, M. M., Botha, H., Martin, P. R., Schwarz, C. G., Senjem, M. L., et al. (2019) · Brain · doi:10.1093/brain/awz157 · Cited by 55
Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology
Rocha, N. P., Charron, O., Latham, L. B., Colpo, G. D., Zanotti-Fregonara, P., Yu, M., Freeman, L., Furr Stimming, E., & Teixeira, A. L. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000984 · Cited by 52
Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies
Donaghy, P. C., Firbank, M. J., Thomas, A. J., Lloyd, J., Petrides, G., Barnett, N., Olsen, K., & O'Brien, J. T. (2018) · Movement Disorders · doi:10.1002/mds.27403 · Cited by 52
Voigt, R. M., Wang, Z., Brown, J. M., Engen, P. A., Naqib, A., Goetz, C. G., Hall, D. A., Metman, L. V., Shaikh, M., Forsyth, C. B., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105780 · Cited by 51
Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis
Wijeyekoon, R. S., Kronenberg-Versteeg, D., Scott, K. M., Hayat, S., Jones, J. L., Clatworthy, M. R., Floto, R. A., Barker, R. A., & Williams-Gray, C. H. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00870 · Cited by 50
Speech-based characterization of dopamine replacement therapy in people with Parkinson’s disease
Norel, R., Agurto, C., Heisig, S., Rice, J. J., Zhang, H., Ostrand, R., Wacnik, P. W., Ho, B. K., Ramos, V. L., & Cecchi, G. A. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0113-5 · Cited by 45
Ananbeh, H., Novak, J., Juhas, S., Juhasova, J., Klempir, J., Doleckova, K., Rysankova, I., Turnovcova, K., Hanus, J., Hansikova, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105598 · Cited by 46
Kwok, J. Y. Y., Choi, E. P. H., Wong, J. Y. H., Lok, K. Y. W., Ho, M.-H., Fong, D. Y. T., Kwan, J. C. Y., Pang, S. Y. Y., & Auyeung, M. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00452-w · Cited by 43
Dlay, J. K., Duncan, G. W., Khoo, T. K., Williams-Gray, C. H., Breen, D. P., Barker, R. A., Burn, D. J., Lawson, R. A., & Yarnall, A. J. (2020) · Brain Sciences · doi:10.3390/brainsci10020078 · Cited by 44
Metadata
- Authors
- Adams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., Dorsey, E. R., & Sharma, G.
- Venue
- Digital Biomarkers
- Publisher
- S. Karger AG
- Published
- 2017-08-17
- Volume
- 1
- Issue
- 1
- Pages
- 52-63
- ISSN
- 2504-110X (ISSN-L)
- OpenAlex
- W2749718288
- Cited by
- 3,171
- References
- 5
- FWCI
- 98.28
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.